Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14313021 | 0.96 | RIPK1 (0.44) | RIPK1KDM4EMAPTTHRBPIK3CD | |
| SCHEMBL58551 | 0.94 | RIPK1 (0.49) | RIPK1KDM4EMAPTTHRBPIK3CD | |
| SCHEMBL19378008 | 0.89 | RIPK1 (0.44) | RIPK1PIK3CDACVRL1MAP4K4CSNK2A2 | |
| SCHEMBL16021404 | 0.89 | RIPK1 (0.46) | RIPK1PIK3CDCSNK2A2CSNK2A1HPGDS | |
| SCHEMBL5142206 | 0.89 | RIPK1 (0.46) | RIPK1PIK3CDCSNK2A2CSNK2A1HPGDS | |
| SCHEMBL19377750 | 0.88 | MERTK (0.52) | PIK3CDAXLMERTKTYRO3ACVRL1 | |
| SCHEMBL14532094 | 0.85 | RIPK1 (0.45) | RIPK1KDM4EMAPTTHRBAXL | |
| SCHEMBL25172261 | 0.85 | PIK3CD (0.44) | RIPK1PIK3CDAXLMERTKTYRO3 | |
| SCHEMBL19377687 | 0.85 | PIK3CD (0.56) | PIK3CDTYRO3ACVRL1CSNK2A2CSNK2A1 | |
| SCHEMBL22132866 | 0.84 | RIPK1 (0.49) | RIPK1KDM4EMAPTTHRBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534479-B2 | Triazine compound and composition and use thereof | FINDCURE BIOSCIENCES (ZHONGSHAN) CO., LTD. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20250387401-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | INCYTE CORP (US) | 2025-12-25 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4606432-A2 | FORMULATIONS OF AN AXL/MER INHIBITOR | Incyte Corporation (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250188086-A1 | SALTS OF TAM INHIBITORS | INCYTE CORPORATION | 2025-06-12 | — | — | US | disclosed |
| US-12318389-B2 | Formulations of an AXL/MER inhibitor | INCYTE CORPORATION (US) | 2025-06-03 | — | — | US | disclosed |
| EP-3813800-B1 | FORMULATIONS OF AN AXL/MER INHIBITOR | INCYTE CORP (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12187730-B2 | Salts of TAM inhibitors | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240423991-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | INCYTE CORPORATION | 2024-12-26 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | RIPK1 937/4885KDM4E 212/4885MAPT 3577/4885 |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | RIPK1 2081/4885KDM4E 1162/4885MAPT 890/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | RIPK1 1981/4885KDM4E 1275/4885MAPT 923/4885 |
| US-12318389-B2 | Formulations of an AXL/MER inhibitor | AXL, MERTK, RET | RIPK1 1299/4885KDM4E 3619/4885MAPT 198/4885 |
| US-20250188086-A1 | SALTS OF TAM INHIBITORS | PI4KA, PI4KB, PIK3CA | RIPK1 902/4885KDM4E 392/4885MAPT 4009/4885 |
| US-12187730-B2 | Salts of TAM inhibitors | PI4KA, PI4KB, PIK3CA | RIPK1 902/4885KDM4E 392/4885MAPT 4009/4885 |
| US-20240423991-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | AXL, MERTK, RET | RIPK1 1299/4885KDM4E 3619/4885MAPT 198/4885 |
| US-20250387401-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | AXL, MERTK, TYRO3 | RIPK1 796/4885KDM4E 2626/4885MAPT 270/4885 |
| US-12534479-B2 | Triazine compound and composition and use thereof | JAK1, CCR1, PEAK1 | RIPK1 1526/4885KDM4E 3275/4885MAPT 622/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | RIPK1 435/4885KDM4E 769/4885MAPT 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.